London, UK and Ann Arbor, Michigan, US (PRWEB) January 20, 2012
NextGen Group plc (AIM:NGG) is pleased to announce that its US-subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has launched an expanded cerebrospinal fluid (CSF) multiple protein (multiplex) assay, csfdiscovery82, for central nervous system (CNS) biomarker discovery and qualification. The new assay simultaneously measures 82 human CSF proteins that are thought to have potential as biomarkers in CNS diseases, particularly Alzheimer’s, Parkinson’s, multiple sclerosis and ALS diseases. The launch of csfdiscovery82 demonstrates the acceleration in NextGen Sciences strategy of becoming a leading player in the growing CNS biomarker market.
NextGen’s assay is based upon its multiple reaction monitoring (MRM) mass spectrometry platform and generates high precision data (<10% average CV) that clients can use in their drug and diagnostic development programmes. NextGen is now turning its assay development focus onto specific CNS disease/injury areas such as Parkinson’s, multiple sclerosis and traumatic brain injury (TBI) as it begins to develop its diagnostics business model. The company intends to build a multi-parallel project portfolio that can exploit its de novo discovery and targeted assay development capabilities.
Klaus Rosenau, Chairman and CEO of NextGen Group, commented, ‘The release of csfdiscovery82 demonstrates that we have once again delivered on our plans to develop multiplex protein assays that will help to establish the company as a market leader in biomarker discovery and qualification using its MRM technology. Further, it builds upon the desire to develop our reputation within the CNS disease/injury market and advances our progress towards implementing our diagnostics business strategy.’ Rosenau also said, ‘Importantly, we have become stronger in our aims to target increasing market share from the $600M mass spectrometry based biomarker discovery market. We believe this assay and others currently in development will significantly impact the needs of pharmaceutical, biotechnology and diagnostics companies in identifying effective disease progression, stratification and diagnostic biomarkers as we move towards a more personalized medicine era.’
For more information please contact :
Klaus Rosenau, Chairman and CEO
+49 160 551 6756
Jonathan Wright, Nicola Marrin
+44 (0) 20 7107 8000
Notes to Editors
NextGen Sciences Inc (Ann Arbor, MI, USA) is the subsidiary of NextGen Group PLC, London, UK (AIM: NGG). It provides pharmaceutical, biotechnology and diagnostic companies with rapid and quantitative protein biomarker discovery, measurement and qualification services using mass spectrometry technology. With a rise in the industry focus on personalized medicine and cost-effectiveness, biomarkers are playing an increasing important role in drug discovery, development and patient access, as well as healthcare delivery. The global market for biomarkers is expected to grow to $12.8bn by 2012 (BCC Research), with those for neurological disorders ($3.5bn by 2015, Espicom Healthcare) and oncology ($9.5bn by 2014, http://www.marketsandmarkets.com) playing an important role. NextGen Sciences’ products include discovery assays, oncology assays, CNS assays and cardiovascular assays for biomarker discovery and qualification. For more information please visit http://www.nextgensciences.com.